208 related articles for article (PubMed ID: 31888688)
1. Impacts of intellectual property provisions in trade treaties on access to medicine in low and middle income countries: a systematic review.
Islam MD; Kaplan WA; Trachtenberg D; Thrasher R; Gallagher KP; Wirtz VJ
Global Health; 2019 Dec; 15(1):88. PubMed ID: 31888688
[TBL] [Abstract][Full Text] [Related]
2. Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts.
Gleeson D; Lexchin J; Labonté R; Townsend B; Gagnon MA; Kohler J; Forman L; Shadlen KC
Global Health; 2019 Nov; 15(Suppl 1):78. PubMed ID: 31775767
[TBL] [Abstract][Full Text] [Related]
3. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
Adekola TA
Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
[TBL] [Abstract][Full Text] [Related]
4. What is the impact of intellectual property rules on access to medicines? A systematic review.
Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
[TBL] [Abstract][Full Text] [Related]
5. The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines.
Townsend B; Gleeson D; Lopert R
Asia Pac J Public Health; 2016 Nov; 28(8):682-693. PubMed ID: 27920239
[TBL] [Abstract][Full Text] [Related]
6. The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: Implications for domestic legislations in low- and middle-income countries.
Son KB; Lee TJ
Glob Public Health; 2018 Sep; 13(9):1169-1178. PubMed ID: 28585477
[TBL] [Abstract][Full Text] [Related]
7. Access to generic antiretrovirals: inequality, intellectual property law, and international trade agreements.
Castro A; Westerhaus M
Cad Saude Publica; 2007; 23 Suppl 1():S85-96. PubMed ID: 17308722
[TBL] [Abstract][Full Text] [Related]
8. Trade-Related Aspects of Intellectual Property Rights Flexibilities and Public Health: Implementation of Compulsory Licensing Provisions into National Patent Legislation.
McGIVERN L
Milbank Q; 2023 Dec; 101(4):1280-1303. PubMed ID: 37646392
[TBL] [Abstract][Full Text] [Related]
9. [Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].
Chaves GC; Oliveira MA; Hasenclever L; de Melo LM
Cad Saude Publica; 2007 Feb; 23(2):257-67. PubMed ID: 17221075
[TBL] [Abstract][Full Text] [Related]
10. Trade, TRIPS, and pharmaceuticals.
Smith RD; Correa C; Oh C
Lancet; 2009 Feb; 373(9664):684-91. PubMed ID: 19167054
[TBL] [Abstract][Full Text] [Related]
11. The ethics of intellectual property rights in an era of globalization.
Shah AK; Warsh J; Kesselheim AS
J Law Med Ethics; 2013; 41(4):841-51, Table of Contents. PubMed ID: 24446942
[TBL] [Abstract][Full Text] [Related]
12. A multidisciplinary review of the policy, intellectual property rights, and international trade environment for access and affordability to essential cancer medications.
Baxi SM; Beall R; Yang J; Mackey TK
Global Health; 2019 Sep; 15(1):57. PubMed ID: 31533850
[TBL] [Abstract][Full Text] [Related]
13. The high price of "free" trade: U.S. trade agreements and access to medicines.
Lopert R; Gleeson D
J Law Med Ethics; 2013; 41(1):199-223. PubMed ID: 23581666
[TBL] [Abstract][Full Text] [Related]
14. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
Cohen-Kohler JC; Forman L; Lipkus N
Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618
[TBL] [Abstract][Full Text] [Related]
15. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement.
Motari M; Nikiema JB; Kasilo OMJ; Kniazkov S; Loua A; Sougou A; Tumusiime P
BMC Public Health; 2021 Mar; 21(1):490. PubMed ID: 33706726
[TBL] [Abstract][Full Text] [Related]
16. Implications of bilateral free trade agreements on access to medicines.
Correa CM
Bull World Health Organ; 2006 May; 84(5):399-404. PubMed ID: 16710551
[TBL] [Abstract][Full Text] [Related]
17. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
Allard Soto R
Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
[TBL] [Abstract][Full Text] [Related]
18. Intellectual property and access to medicines: mapping public attitudes toward pharmaceuticals during the United States-Mexico-Canada Agreement (USMCA) negotiation process.
Wong ASY; Cole CB; Kohler JC
Global Health; 2021 Aug; 17(1):92. PubMed ID: 34416883
[TBL] [Abstract][Full Text] [Related]
19. Canada and access to medicines in developing countries: intellectual property rights first.
Lexchin J
Global Health; 2013 Sep; 9():42. PubMed ID: 24007595
[TBL] [Abstract][Full Text] [Related]
20. Defending access to medicines in regional trade agreements: lessons from the Regional Comprehensive Economic Partnership - a qualitative study of policy actors' views.
Townsend B
Global Health; 2021 Jul; 17(1):78. PubMed ID: 34238347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]